Rakovina Therapeutics (RKVT.D) Stock Overview
A biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
RKVT.D Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Rakovina Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.47 |
| 52 Week High | CA$100.00 |
| 52 Week Low | CA$0.29 |
| Beta | -0.23 |
| 1 Month Change | 18.00% |
| 3 Month Change | -21.33% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -21.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| RKVT.D | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 15.1% | 0.1% | 3.4% |
| 1Y | n/a | -10.9% | 13.7% |
Return vs Industry: Insufficient data to determine how RKVT.D performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how RKVT.D performed against the US Market.
Price Volatility
| RKVT.D volatility | |
|---|---|
| RKVT.D Average Weekly Movement | 19.8% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 4.0% |
Stable Share Price: RKVT.D's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine RKVT.D's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Mads Daugaard | www.rakovinatherapeutics.com |
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company’s preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Variational AI Inc. to identify and develop novel small-molecule therapies against DNA-damage response (DDR) targets for the treatment of cancer.
Rakovina Therapeutics Inc. Fundamentals Summary
| RKVT.D fundamental statistics | |
|---|---|
| Market cap | US$10.19m |
| Earnings (TTM) | -US$4.02m |
| Revenue (TTM) | n/a |
Is RKVT.D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RKVT.D income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$5.50m |
| Earnings | -CA$5.50m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 58.0% |
How did RKVT.D perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/30 08:46 |
| End of Day Share Price | 2025/06/27 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rakovina Therapeutics Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alexander Rihane | First Berlin Equity Research GmbH |